SCHEMBL198480

SCHEMBL198480

CC(C)(Oc1ccc(OCC(C2CCCCC2)C2(c3ccc(Cl)cc3)Nc3cc(F)c(F)cc3N2)nc1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
MAP4K4 O95819 3/20 0.35
PDE5A O76074 1/20 0.35
KCNH2 Q12809 1/20 0.35
MINK1 Q8N4C8 1/20 0.35
PPARG P37231 5/20 0.33
FABP2 P12104 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
PPARD Q03181 5/20 0.32
LNPEP Q9UIQ6 3/20 0.32
DGAT1 O75907 1/20 0.31
CNR1 P21554 1/20 0.31
CYP4F2 P78329 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL198730 0.91 PPARA (0.41) PPARACYP1A2CYP3A4CNR1
SCHEMBL198388 0.91 PPARA (0.42) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL1843200 0.88 PPARA (0.37) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL1842326 0.88 PTGDR2 (0.34) MAPTMAP4K4
SCHEMBL1840762 0.87 PPARA (0.40) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL1839779 0.85 NR1H4 (0.41) MAP4K4
SCHEMBL198481 0.85 PPARA (0.36) PPARAMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL1839494 0.85 NR1H4 (0.42) CYP3A4CYP2D6KCNH2
SCHEMBL1839238 0.85 NR1H4 (0.42) CYP3A4CYP2D6KCNH2
SCHEMBL1840527 0.84 ADRB3 (0.35) MAPTKMT2AKCNH2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321282-A1 NEW BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-05-18 EP claimed
WO-2010028981-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-18 WO claimed
US-8088930-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-01-03 US disclosed
EP-2321282-A1 NEW BENZIMIDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010028981-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-18 WO disclosed
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063101-A1 NEW BENZIMIDAZOLE DERIVATIVES CYP3A7, ECI1, CYP2B6 PPARA 322/4885MEN1 2514/4885CYP1A2 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.